celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Company profile
Ticker
CLDX
Exchange
Website
CEO
Anthony Marucci
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Celldex Therapeutics Switzerland GmbH ...
IRS number
133191702
CLDX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
1 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
28 Feb 24
424B5
Prospectus supplement for primary offering
26 Feb 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
26 Feb 24
8-K
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
8 Nov 23
424B5
Prospectus supplement for primary offering
8 Nov 23
Latest ownership filings
4
Freddy A. Jimenez
15 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G
Kynam Capital Management, LP
14 Feb 24
SC 13G
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
Polar Capital Holdings Plc
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.13 mm | 21.13 mm | 21.13 mm | 21.13 mm | 21.13 mm | 21.13 mm |
Cash burn (monthly) | 2.36 mm | (no burn) | 13.75 mm | 11.23 mm | 6.33 mm | 8.04 mm |
Cash used (since last report) | 16.32 mm | n/a | 94.91 mm | 77.56 mm | 43.71 mm | 55.53 mm |
Cash remaining | 4.82 mm | n/a | -73.78 mm | -56.43 mm | -22.58 mm | -34.40 mm |
Runway (months of cash) | 2.0 | n/a | -5.4 | -5.0 | -3.6 | -4.3 |
Institutional ownership, Q3 2023
90.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 143 |
Opened positions | 17 |
Closed positions | 23 |
Increased positions | 60 |
Reduced positions | 42 |
13F shares | Current |
---|---|
Total value | 1.38 tn |
Total shares | 50.54 mm |
Total puts | 488.67 k |
Total calls | 565.30 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
FMR | 7.09 mm | $195.09 bn |
Wellington Management | 5.43 mm | $149.48 bn |
RTW Investments | 3.46 mm | $95.31 bn |
BLK Blackrock | 3.25 mm | $89.49 bn |
Kynam Capital Management | 3.20 mm | $88.06 bn |
Vanguard | 2.62 mm | $72.06 bn |
Polar Capital | 2.43 mm | $66.78 bn |
STT State Street | 2.29 mm | $63.10 bn |
BLVGF Bellevue | 1.90 mm | $52.29 bn |
Pictet Asset Management Holding | 1.85 mm | $50.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Martin Samuel Bates | Common Stock | Option exercise | Acquire M | No | No | 2.78 | 10,750 | 29.89 k | 35,128 |
2 Jan 24 | Martin Samuel Bates | Incentive Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.78 | 10,750 | 29.89 k | 0 |
15 Jun 23 | Shoos Karen L. | NQSO Common Stock | Grant | Acquire A | No | No | 36.87 | 11,300 | 416.63 k | 11,300 |
15 Jun 23 | Cohen Cheryl | NQSO Common Stock | Grant | Acquire A | No | No | 36.87 | 11,300 | 416.63 k | 11,300 |
15 Jun 23 | Marino James J | NQSO Common Stock | Grant | Acquire A | No | No | 36.87 | 11,300 | 416.63 k | 11,300 |
15 Jun 23 | Conrad Herbert J | NQSO Common Stock | Grant | Acquire A | No | No | 36.87 | 11,300 | 416.63 k | 11,300 |
News
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
17 Apr 24
Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
22 Mar 24
Market-Moving News for March 15th
15 Mar 24
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
1 Mar 24
Reported Earlier, Celldex Therapeutics Prices Upsized $400M Public Offering Of 8.52M Common Stock At $47/Share
1 Mar 24
Press releases
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
17 Apr 24
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
8 Mar 24
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
5 Mar 24
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
5 Mar 24
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
29 Feb 24